Contact Us

Professional Diabetes Education

The Mary & Dick Allen Diabetes Center strives to become the "go to" community resource for diabetes for the general public as well as for health care professionals.

Annual activities include:

Diabetes: What’s New? What’s Next? - 2016 - CME Conference
Saturday, October 29, 2016 - 8:00 AM - 3:00 PM
Hotel Irvine
Course Director: Daniel A. Nadeau, MD
Target Audience: Physicians, Certified Diabetes Educators, Pharmacists, Registered Nurses and Registered Dietitians

Hoag Annual Diabetes Conference for Health Care Professionals

Diabetes & Reproductive Health Practice Recommendations SSEP Associate Training

Internship positions for MPH students from UCI

Elective rotations for pharmacy students from Western University

Internship placements for a broad array of other health care professionals, including dietitians, social workers, and pharmacists.


The Mary & Dick Allen Diabetes Center works closely with local universities, pharmaceutical and device manufacturers to develop new methods & technologies for treating diabetes effectively.

Daniel Nadeau, M.D., Program Director of the Mary & Dick Allen Diabetes Center at Hoag Hospital Memorial Presbyterian and Dr. Kris V. Iyer Endowed Chair in Diabetes Care, is the principal investigator for a new type 2 diabetes trial at Hoag Medical Group.

Hoag Medical Group is currently enrolling patients in a study to evaluate the effect of Farxiga on blood glucose level and renal safety in patients with type 2 diabetes mellitus and reduced kidney function. Farxiga is approved by the US FDA for the treatment of type 2 diabetes, but not approved by the FDA for the treatment of type 2 diabetes in people with moderate renal disease. The purpose of this study is to find out if Farxiga is effective in decreasing blood glucose level, body weight and blood pressure, when it is added to existing diabetes therapy and whether it causes any side effects in adult patients with moderate renal disease (renal impairment) with Type 2 diabetes mellitus, who are not currently in good glucose control.

Patients may be eligible to join the study if they…

  • Have a history of Type 2 diabetes mellitus for more than 12 months
  • Female or male aged ≥18 years and <75 years
  • Have an HbA1c ≥ 7.0% and ≤ 11%
  • Have renal impairment with an eGFR 40-65 mL/minute/1.73m2

For more information or to schedule a study appointment please call the HMG Research Department at 949-791-3049.

Diabetes Study involving Women with Gestational Diabetes

The research team at the Mary & Dick Allen Center recently received ethics board approval to conduct its first study involving women with gestational diabetes. Gestational diabetes mellitus (GDM) could develop during pregnancy and is characterized by persistent high blood glucose (BG) levels in the patient. Unmanaged high BG levels can increase the risk of various health complications for both the mother and the growing baby. Women diagnosed with GDM are also at a greater risk of developing type 2 diabetes. The overall prevalence of GDM is around 9% in the US however, certain ethnic groups (e.g. Latinos, Asians, and African Americans) are at a significantly higher risk compared to others.

The research team led by Dr. Harsimran Singh will undertake systematic review of medical records of women with diagnosed with GDM to identify various demographic and clinical factors that may pose as risk factors for GDM in women from different ethnic groups. Subsequently, interviews will be conducted with a randomly selected sample of women representing different ethnicities to improve our understanding of patients’ experiences of GDM, its management, and factors that may improve its management.

For more information about the study, please contact:

Dr. Harsimran “Sim” Singh at (949)764-7357 or email: [email protected]